Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
life sciences
national
national blog main
national top stories
raleigh-durham blog main
raleigh-durham top stories
3
×
san francisco blog main
3
×
san francisco top stories
biogen
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
akouos
alex azar
allergan
alliance for aging research
alnylam pharmaceuticals
amag pharmaceuticals
amgen
amunix
anirvan ghosh
aspire capital fund
What
plans
3
×
acquisitions
administration
angry
announced
anti
benefited
bio
cash
ceo
clearance
collabs
company
covid
crunch
daniel
deal
despite
didn’t
drug
end
fda
fear
gilead
gilead’s
goal
help
industry
introduce
ipo
losing
medical
medical’s
medicines
meet
month
needs
o’day
pharma
presidential
Language
unset
Current search:
plans
×
" san francisco blog main "
×
" raleigh-durham top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans